ClinicalTrials.gg
Not yet recruitingNCT04921397CASES-TCMUpdated Jun 10, 2021

China Stroke Registry for Patients With Traditional Chinese Medicine

An observational study in Ischemic Stroke and Intracerebral Hemorrhage, sponsored by Dongzhimen Hospital, Beijing. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-10.

Sponsored by Dongzhimen Hospital, Beijing · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
20,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing — 6 open to participants now, 6 under way, none of them phase 3. Ischemic Stroke · Dongzhimen Hospital, Beijing.

Started
2021
with 1 other
Observational
6 of 16
4 open now
Registered
7th of 16
by date

Among the 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing, this one is one of 2 that started in 2021, is one of 6 observational ones, and was the 7th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

6 of the 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Ischemic Stroke by Dongzhimen Hospital, Beijing, or all of them as a file.
02

Study summary

The CASES-TCM study is a prospective, multicenter, observational study, which will enroll 20,000 patients with acute stroke (ischemic stroke or intracerebral hemorrhage) within 7 days of symptom onset.

This study attempts to depict major clinical characteristics of acute stroke in patients with Chinese medicine treatment and to explore any difference compared with other non-Chinese medicine use cohorts and the effectiveness and safety of Chinese medicine.

03

Conditions studied

  • Ischemic Stroke
  • Intracerebral Hemorrhage
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who meet the criteria will be consecutively enrolled from 100 participating sites in China.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • Diagnosed as acute ischemic stroke or intracerebral hemorrhage
  • Within 7 days of symptom onset

Exclusion criteria

Exclusion Criteria:

  • Refusal to give
  • Have difficulties completing follow-up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
20,000 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Distribution of scores on the modified Rankin scale at 3-month follow-up

    Modified Rankin Scale, a commonly used scale for measuring the degree of dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. 0 - No symptoms.1 -No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.3 - Moderate disability. Requires some help, but able to walk unassisted.4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.6 - Dead.

    Time frame: 3 months follow-up

  2. Recurrent stroke events (ischemic stroke, hemorrhagic stroke including intracerebral hemorrhage and subarachnoid hemorrhage) within 12-month follow-up

    Number of patients with new ischemic stroke and hemorrhagic stroke within 12 months of follow-up.

    Time frame: 12 months follow-up

Secondary outcomes

  1. Proportion of patients receive Chinese medicine treatment within 24 hours after admission

    Chinese medicine treatment exposure defined as whether patients receive Chinese medicine injection, oral Chinese patent medicine, or compound Chinese medicine.

    Time frame: 24 hours after admission

  2. Chinese medicine treatment duration within 3-month, 12-month, and 24-month follow-up

    Chinese medicine treatment duration will be assessed using proportion of days covered, which is a percentage of days covered with the medicine in the number of days the patient is eligible to have the medication.

    Time frame: 3 months, 12 months, and 24 months follow-up

  3. Change in the National Institutes of Health Stroke Scale score between baseline (admission) and discharge

    National Institute of Health Stroke Scale is a tool used by healthcare providers to objectively quantify the impairment caused by a stroke. It is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.

    Time frame: At admission (baseline) and discharge (14 days - mean for length of hospitalization for stroke patients)

  4. Patient-Reported Outcomes Scale for Stroke score at discharge

    Patient-Reported Outcomes Scale for Stroke, a structured questionnaire-scale was developed suitable for Chinese patients. The score ranges from 0 (best) to 144 (worst).

    Time frame: At discharge (14 days - mean for length of hospitalization for stroke patients)

  5. Proportion of patients with modified Rankin Scale score ≤2 at 3-month and 12-month follow-up

    Modified Rankin Scale, a commonly used scale for measuring the degree of dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. 0 - No symptoms.1 -No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.3 - Moderate disability. Requires some help, but able to walk unassisted.4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.6 - Dead.

    Time frame: 3 months, 12 months follow-up

  6. Distribution of scores on the modified Rankin scale at 12-month follow-up

    Modified Rankin Scale, a commonly used scale for measuring the degree of dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. 0 - No symptoms.1 -No significant disability. Able to carry out all usual activities, despite some symptoms.2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.3 - Moderate disability. Requires some help, but able to walk unassisted.4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.6 - Dead.

    Time frame: 12 months follow-up

  7. Proportion of patients with Barthel Index score ≥90 at 3-month and 12-month follow-up

    Barthel Index is a commonly used scale for measuring the activity of daily living of people. Score of 10-item scale ranges from 0 (worst) to 100 (best).

    Time frame: 3 months, 12 months follow-up

  8. Recurrent stroke events (ischemic stroke, hemorrhagic stroke including intracerebral hemorrhage and subarachnoid hemorrhage) within 3-month and 24-month follow-up

    Number of patients with new ischemic stroke and hemorrhagic stroke events within 3 months and 24 months of follow-up.

    Time frame: 3 months, 24 months follow-up

  9. Composite of new clinical vascular events within 3-month, 12-month, and 24-month follow-up

    Number of patients with new clinical vascular events (ischemic stroke/ hemorrhagic stroke/ transient ischemic attack / myocardial infarction /vascular death) within 3 months, 12 months, and 24 months of follow-up.

    Time frame: 3 months, 12 months, 24 months follow-up

  10. Mini-Mental State Examination scale score at 3-month, 12-month, and 24-month follow-up

    Mini-Mental State Examination scale is a commonly used scale for measuring the cognitive function. Range: 0 to 30 points, higher points represent a better outcome.

    Time frame: 3 months, 12 months, 24 months follow-up

  11. All-cause mortality within 12-month and 24-month follow-up

    Number of patients who died within 12 months and 24 months of follow-up.

    Time frame: 12 months, 24 months follow-up

  12. Incidence of adverse events

    Number of patients with any adverse events (including serious adverse events) during the study.

    Time frame: Up to 24 months follow-up

07

Study locations

1 site
08

References and documents

Publications

  • Feng L, Kong L, Dong X, Lai X, Zhang D, Ren B, Liu S, Xie X, Li C, Song Y, Du Y, Cao K, Zhang C, Gao Y; CASES-TCM Protocol Steering Group. China Stroke Registry for Patients With Traditional Chinese Medicine (CASES-TCM): Rationale and Design of a Prospective, Multicenter, Observational Study. Front Pharmacol. 2021 Aug 31;12:743883. doi: 10.3389/fphar.2021.743883. eCollection 2021. PubMed 34531755 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2021; primary completion for Dec 2024, 42 months later.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 42 months is below that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2021
First posted
Jun 10, 2021
StartEst.
Jun 11, 2021
Primary completionEst.
Dec 31, 2024
CompletionEst.
Jun 1, 2025
Last update
Jun 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04921397
Lead sponsor
Dongzhimen Hospital, Beijing
Responsible party
Ying Gao (President of Institute for Brain Disorders, Beijing University of Chinese Medicine, Dongzhimen Hospital, Beijing) — Principal investigator
First posted
Jun 10, 2021
Start date
Jun 11, 2021 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Jun 1, 2025 (estimated)
Last update
Jun 10, 2021

Study contacts

Ying Gao
Contact
gaoying973@163.com
+86-10-84013209
Ying Gao
principal investigator · Dongzhimen Hospital, Beijing

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion